Presseportal.de - Trending Pharmaceuticals & Sciencehttp://www.presseportal.de/en/top/pharmaceuticalsPresseportal - the leading German database for press releases - a service of news aktuell, a company of the dpa Group en-ennews aktuell GmbHhttp://www.presseportal.de/images/logos/logo-de-250.jpgPresseportal.de - Trending Pharmaceuticals & Sciencehttp://www.presseportal.de/en/top/pharmaceuticalsGrünenthal and Mundipharma enter commercial partnership in ChinaGrünenthal Group: Aachen(Beijing (ots) - Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market and distribute Grünenthal's Tramal® (tramadol) in China from May 1, 2018. ...https://www.presseportal.de/en/pm/118252/3839214Mon, 15 Jan 2018 06:00:10 +0100CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic DiseaseUCB Pharma: Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and ...https://www.presseportal.de/en/pm/55232/3834196Tue, 09 Jan 2018 07:01:09 +0100Takeda Announces Intention to Acquire TiGenixTakeda Pharmaceutical Company Limited: Osaka, Japan (ots/PRNewswire) - Expands Takeda's Late Stage Pipeline and Leadership in Gastroenterology Acquisition Highlights - Deal reinforces Takeda's commitment to patients living with Inflammatory Bowel Disease (IBD), an area of high unmet ...https://www.presseportal.de/en/pm/77160/3831485Fri, 05 Jan 2018 08:03:15 +0100Takeda Announces Intention to Acquire TiGenixTakeda Pharmaceutical Company Limited: Osaka, Japan (ots/PRNewswire) - Expands Takeda's Late Stage Pipeline and Leadership in Gastroenterology Acquisition Highlights - Deal reinforces Takeda's commitment to patients living with Inflammatory Bowel Disease (IBD), an area of high unmet ...https://www.presseportal.de/en/pm/77160/3831458Fri, 05 Jan 2018 07:24:40 +0100New DEA CEO: "Adapt and adjust"DEA Deutsche Erdoel AG: Hamburg (ots) - Maria Moraeus Hanssen announces a time for change on her first day as CEO and Chairman of the Board of Management of DEA Deutsche Erdoel AG. "I am starting at DEA in a very interesting time for the company and for the business as a ...https://www.presseportal.de/en/pm/116249/3830951Thu, 04 Jan 2018 12:08:51 +0100FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell CarcinomaMerck KGaA: Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin ...https://www.presseportal.de/en/pm/6873/3822487Thu, 21 Dec 2017 19:09:27 +0100New European real-world audit data provides additional information on the effectiveness of Zebinix® (eslicarbazepine acetate) for the treatment of partial-onset epilepsy in adultsEisai: Porto, Portugal and Hatfield, England (ots/PRNewswire) - - Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, US.[1],[2],[3] Bial and Eisai have announced new real-world audit data ...https://www.presseportal.de/en/pm/80515/3813937Tue, 12 Dec 2017 16:43:38 +0100Once-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER StudyDaiichi Sankyo Europe GmbH: Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) ...https://www.presseportal.de/en/pm/62920/3813715Tue, 12 Dec 2017 13:53:50 +0100KfW capital market activities 2018 / Focus on liquidity and sustainabilityKfW: Frankfurt am Main (ots) - - Liquidity is key: KfW benchmark bonds enjoy huge success - Potential increase to outstanding euro benchmarks - Commitment to responsibility on the capital market comes to fruition - KfW plans to raise EUR 70 to 75 billion ...https://www.presseportal.de/en/pm/41193/3812034Mon, 11 Dec 2017 10:30:19 +0100Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World SettingNovo Nordisk A/S: Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar ...https://www.presseportal.de/en/pm/57206/3811920Mon, 11 Dec 2017 09:02:05 +0100